AIMS A population pharmacokinetic (PK) analysis was performed to: (1) characterise the PK of unbound and total mycophenolic acid (MPA) and its 7-O-mycophenolic acid glucuronide (MPAG) metabolite, and (2) identify the clinically significant covariates that cause variability in the dose-exposure relationship to facilitate dose optimisation.METHODS A total of 740 unbound MPA (uMPA), 741 total MPA (tMPA) and 734 total MPAG (tMPAG) concentration-time data from 58 Chinese kidney transplant patients were analysed using a nonlinear mixed-effect model. The influence of covariates was tested using a stepwise procedure.
RESULTSThe PK of unbound MPA and MPAG were characterised by a two-and one-compartment model with first-order elimination, respectively. Apparent clearance of uMPA (CL uMPA /F) was estimated to be 852 L/h with a relative standard error (RSE) of 7.1%. The tMPA and uMPA were connected using a linear protein binding model, in which the protein binding rate constant (k B ) increased non-linearly with the serum albumin (ALB) concentration. The estimated k B was 53.4 /h (RSE, 2.3%) for patients with ALB of 40 g/L. In addition, model-based simulation showed that changes in ALB substantially affected tMPA but not uMPA exposure. CONCLUSIONS The established model adequately described the population PK characteristics of the uMPA, tMPA, and MPAG. The estimated CL uMPA /F and unbound fraction of MPA (FU MPA ) in Chinese kidney transplant recipients were comparable to those published previously in Caucasians. We recommend monitoring uMPA instead of tMPA to optimise mycophenolate mofetil (MMF) dosing for patients with lower ALB levels.
Keywordspopulation pharmacokinetics, unbound mycophenolic acid, linear protein binding, adult kidney transplant recipients tMPA population PK [17][18][19][20][21][22][23][24][25][26]. There are few investigations of the population PK characteristics of unbound MPA (uMPA) [27][28][29][30], the pharmacologically active component, due to the technical complexity of measurements. Furthermore, little is known in Chinese kidney transplant recipients.Therefore, the aims of this study were to develop a population PK model to: (1) characterise the PK of uMPA, tMPA, and the metabolite MPAG, and (2) identify the clinically significant covariates that cause variability in the dose-exposure relationship to facilitate dose optimisation.
Methods
Study design and patientsThe data were obtained from two clinical studies conducted in 58 Chinese adult kidney transplant recipients [31,32]. All recipients received triple immunosuppressive therapy comprising MMF (CellCept®, Roche Pharma Ltd., Shanghai, China), CsA, and corticosteroids. The first study was an evaluation of the PK of MPA and MPAG during the early post-transplantation period conducted at Huashan Hospital, Fudan University [31]. MMF was initiated at 1500 mg/day from the day of the surgery. The second study was an open-label, multi-centre, two-phase, sequential, bioequivalence study conducted in stable kidney transplantation patients [32]. MMF dose wa...